From the Departments of Radiology.
Neurological Surgery, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Clin Nucl Med. 2021 Sep 1;46(9):772-773. doi: 10.1097/RLU.0000000000003699.
18F-THK5351 was initially developed to target tau aggregates in neurofibrillary tangles. However, it was also shown to bind to an enzyme, monoamine oxidase B, which is highly expressed in the outer mitochondrial membrane of astrocytes. In a case with glioblastoma, both l-[methyl-11C]-methionine PET and 18F-THK5351 PET showed increased uptake in the tumor. On the other hand, in another case with primary central nervous system lymphoma, l-[methyl-11C]-methionine PET showed increased uptake in the tumor, but 18F-THK5351 PET showed no abnormal uptake in the tumor. 18F-THK5351 PET might be helpful in differentiating between glioblastoma and primary central nervous system lymphoma.
18F-THK5351 最初被开发用于靶向神经纤维缠结中的 tau 聚集物。然而，它也被证明可以与一种酶，单胺氧化酶 B 结合，这种酶在外层线粒体膜中的星形胶质细胞中高度表达。在胶质母细胞瘤的病例中，l-[甲基-11C]-蛋氨酸 PET 和 18F-THK5351 PET 均显示肿瘤摄取增加。另一方面，在另一个原发性中枢神经系统淋巴瘤的病例中，l-[甲基-11C]-蛋氨酸 PET 显示肿瘤摄取增加，但 18F-THK5351 PET 显示肿瘤无异常摄取。18F-THK5351 PET 可能有助于区分胶质母细胞瘤和原发性中枢神经系统淋巴瘤。
